Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders

Marco Pignatelli, Marco Feligioni, Sonia Piccinin, Gemma Molinaro, Ferdinando Nicoletti, Robert Nisticò

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

The term "Autism Spectrum" is often used to describe disorders that are currently classified as Pervasive Developmental Disorders. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and/or cognitive delays or mental retardation; sometimes they present high comorbidity rates with epilepsy. Although these diagnoses share some common features, individuals with these disorders are thought to be "on the spectrum" because of differences in severity across these domains. Recent advances in the genetics of autism spectrum disorders (ASDs) are offering new valuable insights into molecular and cellular mechanisms of pathology. Of particular interest are transgenic technologies that allowed the engineering of several mouse models mimicking different kinds of monogenic heritable forms of ASDs. These transgenic models provide excellent opportunities to explore in detail cellular and molecular mechanisms underlying disease pathology and to identify novel targets for therapeutic intervention. Increasing evidence suggests that the pathophysiological core of the murine model is primarily due to changes in normal synaptic transmission and plasticity. Here, we will extensively review the synaptic alterations across different animal models of ASDs and recapitulate the pharmacological strategies aimed at rescuing hippocampal plasticity phenotypes. We describe how pharmacological modulation of mGlu5 receptor, through the use of positive or negative allosteric modulators (depending on the specific disorder), may represent a promising therapeutic strategy for ASDs treatment.

Original languageEnglish (US)
Pages (from-to)6480-6490
Number of pages11
JournalCurrent Pharmaceutical Design
Volume19
Issue number36
DOIs
StatePublished - Nov 25 2013

Fingerprint

Neuronal Plasticity
Autistic Disorder
Genes
Pharmacology
Pathology
Therapeutics
Synaptic Transmission
Intellectual Disability
Comorbidity
Epilepsy
Animal Models
Communication
Technology
Phenotype
Autism Spectrum Disorder

Keywords

  • Long-term depression
  • Long-term potentiation
  • MGLURs
  • Monogenic autism
  • Synaptic plasticity

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders. / Pignatelli, Marco; Feligioni, Marco; Piccinin, Sonia; Molinaro, Gemma; Nicoletti, Ferdinando; Nisticò, Robert.

In: Current Pharmaceutical Design, Vol. 19, No. 36, 25.11.2013, p. 6480-6490.

Research output: Contribution to journalReview article

Pignatelli, Marco ; Feligioni, Marco ; Piccinin, Sonia ; Molinaro, Gemma ; Nicoletti, Ferdinando ; Nisticò, Robert. / Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders. In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 36. pp. 6480-6490.
@article{144dcd9b5fc64b23973230f16ebc4fa2,
title = "Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders",
abstract = "The term {"}Autism Spectrum{"} is often used to describe disorders that are currently classified as Pervasive Developmental Disorders. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and/or cognitive delays or mental retardation; sometimes they present high comorbidity rates with epilepsy. Although these diagnoses share some common features, individuals with these disorders are thought to be {"}on the spectrum{"} because of differences in severity across these domains. Recent advances in the genetics of autism spectrum disorders (ASDs) are offering new valuable insights into molecular and cellular mechanisms of pathology. Of particular interest are transgenic technologies that allowed the engineering of several mouse models mimicking different kinds of monogenic heritable forms of ASDs. These transgenic models provide excellent opportunities to explore in detail cellular and molecular mechanisms underlying disease pathology and to identify novel targets for therapeutic intervention. Increasing evidence suggests that the pathophysiological core of the murine model is primarily due to changes in normal synaptic transmission and plasticity. Here, we will extensively review the synaptic alterations across different animal models of ASDs and recapitulate the pharmacological strategies aimed at rescuing hippocampal plasticity phenotypes. We describe how pharmacological modulation of mGlu5 receptor, through the use of positive or negative allosteric modulators (depending on the specific disorder), may represent a promising therapeutic strategy for ASDs treatment.",
keywords = "Long-term depression, Long-term potentiation, MGLURs, Monogenic autism, Synaptic plasticity",
author = "Marco Pignatelli and Marco Feligioni and Sonia Piccinin and Gemma Molinaro and Ferdinando Nicoletti and Robert Nistic{\`o}",
year = "2013",
month = "11",
day = "25",
doi = "10.2174/1381612811319360008",
language = "English (US)",
volume = "19",
pages = "6480--6490",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - Synaptic plasticity as a therapeutic target in the treatment of autism-related single-gene disorders

AU - Pignatelli, Marco

AU - Feligioni, Marco

AU - Piccinin, Sonia

AU - Molinaro, Gemma

AU - Nicoletti, Ferdinando

AU - Nisticò, Robert

PY - 2013/11/25

Y1 - 2013/11/25

N2 - The term "Autism Spectrum" is often used to describe disorders that are currently classified as Pervasive Developmental Disorders. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and/or cognitive delays or mental retardation; sometimes they present high comorbidity rates with epilepsy. Although these diagnoses share some common features, individuals with these disorders are thought to be "on the spectrum" because of differences in severity across these domains. Recent advances in the genetics of autism spectrum disorders (ASDs) are offering new valuable insights into molecular and cellular mechanisms of pathology. Of particular interest are transgenic technologies that allowed the engineering of several mouse models mimicking different kinds of monogenic heritable forms of ASDs. These transgenic models provide excellent opportunities to explore in detail cellular and molecular mechanisms underlying disease pathology and to identify novel targets for therapeutic intervention. Increasing evidence suggests that the pathophysiological core of the murine model is primarily due to changes in normal synaptic transmission and plasticity. Here, we will extensively review the synaptic alterations across different animal models of ASDs and recapitulate the pharmacological strategies aimed at rescuing hippocampal plasticity phenotypes. We describe how pharmacological modulation of mGlu5 receptor, through the use of positive or negative allosteric modulators (depending on the specific disorder), may represent a promising therapeutic strategy for ASDs treatment.

AB - The term "Autism Spectrum" is often used to describe disorders that are currently classified as Pervasive Developmental Disorders. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and/or cognitive delays or mental retardation; sometimes they present high comorbidity rates with epilepsy. Although these diagnoses share some common features, individuals with these disorders are thought to be "on the spectrum" because of differences in severity across these domains. Recent advances in the genetics of autism spectrum disorders (ASDs) are offering new valuable insights into molecular and cellular mechanisms of pathology. Of particular interest are transgenic technologies that allowed the engineering of several mouse models mimicking different kinds of monogenic heritable forms of ASDs. These transgenic models provide excellent opportunities to explore in detail cellular and molecular mechanisms underlying disease pathology and to identify novel targets for therapeutic intervention. Increasing evidence suggests that the pathophysiological core of the murine model is primarily due to changes in normal synaptic transmission and plasticity. Here, we will extensively review the synaptic alterations across different animal models of ASDs and recapitulate the pharmacological strategies aimed at rescuing hippocampal plasticity phenotypes. We describe how pharmacological modulation of mGlu5 receptor, through the use of positive or negative allosteric modulators (depending on the specific disorder), may represent a promising therapeutic strategy for ASDs treatment.

KW - Long-term depression

KW - Long-term potentiation

KW - MGLURs

KW - Monogenic autism

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=84886777623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886777623&partnerID=8YFLogxK

U2 - 10.2174/1381612811319360008

DO - 10.2174/1381612811319360008

M3 - Review article

C2 - 23432715

AN - SCOPUS:84886777623

VL - 19

SP - 6480

EP - 6490

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 36

ER -